Huixin Life Technology
announcement
Solemn statement
Huixin Life Science and Technology is a high-tech enterprise, mainly engaged in the research and development of new products, new processes and new technologies in the field of biotechnology and the transformation of achievements.
Important statement: Huixin Life Technology only provides technical support and technical services for partners, and this public account is the only WeChat official platform of "Huixin Life Technology".
Important Notice: Recently, there have been individuals and institutions that imitate huixin life staff and promote various products. Huixin Life reminds you to improve your awareness of fraud prevention, protect personal information, seriously identify the authenticity of its promotional content, increase your vigilance and awareness of prevention, and beware of being deceived.
As a valuable life resource, stem cells have broad application prospects in the field of medical research. With the rapid development of stem cell technology and the popularization of stem cell awareness, people's understanding of stem cells has gradually deepened.
However, most people still don't know what the difference is between "storing cords" and "storing cord blood" is. In fact, these two are talking about umbilical cord mesenchymal stem cells and umbilical cord blood hematopoietic stem cells, so what is the difference between the two?
Why are cord blood and cord/placental stem cells different?
01
Cord blood is also a kind of life resources, belongs to unipotent stem cells, can only differentiate into blood cells, the American Society of Blood and Bone Marrow Transplantation, Chinese perinatal medicine have encouraged healthy families around the world to donate their baby's umbilical cord blood to the public bank!
Umbilical cord mesenchymal stem cells are pluripotent stem cells and can induce differentiation into neural stem cells, liver cells, and vascular stem cells as needed.
Umbilical cord/placental mesenchymal stem cells are derived from the umbilical cord/placental tissue at birth of newborns, and are a type of stem cells obtained by culture and extraction of umbilical cord/placental tissue.
Cord blood hematopoietic stem cells are derived from the blood left over from the fetus, ligated and broken in the placenta and umbilical cord, which is rich in hematopoietic stem cells.
Cord mesenchymal stem cells vs umbilical cord blood hematopoietic stem cells
Umbilical cord stem cells with
What is the difference between other stem cells?
The applicable population also varies 02
Umbilical cord/placenta mesenchymal stem cells have perfect histocompatibility, are safe and secure to use among family members, have high bioavailability, and do not need to be matched, which can achieve one-person storage and benefit the whole family.
Cord blood hematopoietic stem cells need to be strictly matched, and can only be used after successful matching. A single serving of cord blood hematopoietic stem cells that meet the storage criteria is theoretically only available once for children weighing less than 30 kg.
The types of diseases that can be treated are also different 03
Umbilical cord mesenchymal stem cells are widely used, can be used for a variety of tissue and organ damage repair caused by aging and lesions, mainly in refractory and high-incidence diseases, such as leukemia, diabetes, cirrhosis, cardiovascular and cerebrovascular diseases, progressive muscular dystrophy, systemic lupus erythematosus, etc., and can be combined with hematopoietic stem cells to greatly improve the efficacy of blood diseases. Up to now, it covers more than 180 kinds of diseases, so it has a broader clinical application value.
Cord blood hematopoietic stem cells are currently mainly used for the treatment of a variety of malignant and non-malignant blood diseases.
It is worth mentioning that the immunomodulatory function based on mesenchymal stem cells has also shown great potential in the exploration of the treatment of new crown pneumonia. Also about its other application progress. The latest research results published by Academician Wang Fusheng in the International Journal of Hepatology (Hepatology International) show that umbilical cord-derived mesenchymal stem cells significantly improve liver function and long-term survival rate of decompensated cirrhosis.
summary
"The clinical application potential of placenta and umbilical cord is great, and families with economic conditions may consider storing umbilical cords or umbilical cord mesenchymal stem cells"
Although the commercial operation has led to a lot of publicity deviations, the role of placenta, umbilical cord or cord blood cannot be denied because of these commercial publicity biases. Placenta and umbilical cord have wide prospects for clinical application, combined with cord blood stem cell transplantation, which can reduce GVHD, which is embodied in the immunomodulatory biological characteristics of mesenchymal stem cells.
The use of mesenchymal stem cells in allogenes does not require matching, and the closer the blood, the lower the probability of immune rejection;
Parental storage of mesenchymal stem cells, which can be used by the whole family many times, is the health protection of the whole family;
The collection of placenta and umbilical cord is mainly to preserve the mesenchymal stem cells inside, and the collection process will not cause any harm to the baby and mother.
These stem cells are stored and can be used as they go, and the baby keeps it for himself, benefiting the whole family. With the rapid development of stem cell science and more and more clinical applications of stem cells, newborn stem cell storage will become a new choice for more family protection and family health.
Learn more about health